


Australia launches \$1.5M vaccine and immunobiology lab

15 July 2021 | News

The new laboratory focuses on new and emerging areas of therapeutic interest, including RNA vaccines, siRNA/miRNA clinical targets, and gene therapy studies



Australia-based Agilex Biolabs has launched its new \$1.5M vaccine and immuno-biology laboratory. The facility, the most sophisticated in APAC, will attract biotechs and pharma from around the world for advanced clinical research. Premier of South Australia, Steven Marshall launched the new facility on July 15, 2021.

Agilex Biolabs CEO Jason Valentine said, "This new facility adds digital droplet quantitative RT-PCR analysis for RNA, siRNA and miRNA clinical trials, including vaccines and gene therapy trials. We are also installing an EliSPOT/FluoroSPOT multi-spot reader for vaccine studies to enable extrapolation of recall immune responses, which coupled with our state-of-the-art BD FACSymphony 5 laser, 20 colour flow cytometer, offers unparalleled sensitivity for immunology and vaccine trials".

This Agilex Biolabs facility adds to the recent expansion of the small molecule/novel chemical entity laboratory and implementation of the latest 6500+ Sciex LC/MS/MS platforms to enable the development and validation of the highest sensitivity assays in the region for regulated bioanalysis.

The laboratory will be completed in the next few months with international clients already booked to access the advanced technology and scientific excellence. Agilex Biolabs has more than 130 staff which includes 85 dedicated laboratory staff, and supports client pharma and biotech companies from US, Europe and APAC.

The company offers services for both small molecules and biologics for PK, immunogenicity (PD) and biomarker bioanalysis utilising the two platforms of LC-MS/MS and Immunoassay.

IMAGE CAPTION: Premier of South Australia the Hon Steven Marshall MP at the launch